Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 112 (RPL21P112) is a non-functional, processed pseudogene related to the RPL21 gene, which encodes the ribosomal protein L21, a component of the 60S subunit of the ribosome[2][3]. Pseudogenes like RPL21P112 are remnants of gene duplication or retrotransposition events and do not encode functional protein products. Multiple processed pseudogenes related to ribosomal proteins exist in the genome, but they do not participate in ribosome structure or function and are not relevant as therapeutic targets[2][3][4]. RPL21P112 is not a therapeutic target but a non-functional pseudogene, and its inclusion as a druggable target or biomarker is considered incorrect in the context of drug discovery or molecular pharmacology. The functional homolog RPL21 (not the pseudogene) encodes a structural ribosomal protein, but this is a distinct entity[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 112 (RPL21P112).